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691Abstracts
A Markov model, based on data from randomised trials, was
developed to compare the 5 alternative interventions: chlorthali-
done, propranolol, amlodipine, silazapril and losartan. A 
cost-effectiveness analysis was performed, based on numbers-
needed-to-treat (NNT) derived from a published metaanalysis.
The primary outcome measure was the NNT to prevent one fatal
cardiovascular disease event and the secondary outcome measure
was the NNT to prevent one stroke (fatal and nonfatal). Cost
data were derived from public sources. Only direct costs were
considered in the analysis. All costs were calculated from the per-
spective of the public insurance system organisations, in 2003
Euros. Future costs and clinical beneﬁts were discounted at 5%.
The time horizon was 5 years. Sensitivity analyses tested the
effect of modifying the input parameters on the economic end-
points. RESULTS: No signiﬁcant differences in efﬁcacy presented
among drug groups in mild to moderate hypertension. The NNT
for 5 years to prevent one fatal cardiovascular disease event 
was 135.27 patients and to prevent one stroke was just 
64.05 patients. The estimated total cost to prevent one fatal 
cardiovascular disease event was 78,121.40€, 84,040.63€,
118,825.36€, 103,098.82€, and 168,485.60€ for chlorthalidone,
propranolol, amlodipine, silazapril and losartan respectively. The
estimated total cost to prevent one stroke was 36,990.28€,
39,793.02€, 56,263.50€, 48,817.03€ and 79,777.50€ respec-
tively. Sensitivity analysis conﬁrmed the superiority of chlor-
thalidone against the other antihypertensive agents.
CONCLUSIONS: In mild to moderate hypertension, chlorthali-
done is more cost-effective than propranolol, amlodipine, silaza-
pril and losartan and should be considered as the ﬁrst choice of
antihypertensive therapy.
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OBJECTIVE: To asses the economic consequences of antihyper-
tensive treatment with perindopril and enalapril in the elderly,
from the third-party payer perspective. METHODS: The clini-
cal, epidemiological and economic data were derived from a sci-
entiﬁc project conducted among GPs’ in the whole of Poland,
and concerned 159 patients over 65. treated in mono-therapy
within the last year. Calculations were made from the third-party
payer perspective. The retrospective approach was applied. The
direct medical costs of: drug reimbursement, physicians’ consul-
tations, hospitalisation, laboratory and diagnostic tests were
identiﬁed and calculated. Effectiveness was measured by the 
percentage of the patients with appropriately controlled blood
pressure (BP < 140/90mmHg) in accordance with JNC VII guide-
lines. RESULTS: The measured effectiveness of the mono-
therapy was 43% in the perindopril group and 24% in the
enalapril group. Cost of the hospitalisation in the perindopril
group was 54.95% lower than in the enalapril group, which is
equivalent to 89.52€ saved per patient per year. Physicians’ con-
sultations cost reduction in the perindopril group amounted to
15.18€ (21.59%) per patient per year. There was no signiﬁcant
difference in the costs of laboratory and diagnostic tests between
the compared treatments (30.93€ and 27.28€ respectively).
Treatment with perindopril requires additional payer’s expendi-
ture of 18.95€ per patient per year. Total costs measured from
the third-party payer perspective in the perindopril group, were
30.08% lower than in the enalapril group which equalled 82.10€
saved per each patient per year. CONCLUSION: Taking third-
party payer perspective into consideration, mono-therapy with
perindopril is superior to treatment with enalapril in elderly
patients due to better blood pressure control and essential
savings resulting mainly from the reduction of both hospitalisa-
tion and physicians’ consultation costs.
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OBJECTIVE: The purpose of this study was to compare the costs
associated with the prescription of various initial monotherapies
for mild to moderate hypertension in Greece, when following
2003 European Society of Hypertension—European Society of
Cardiology guidelines. In these guidelines, it is concluded that
the 5 major classes of antihypertensive agents are suitable for the
initiation and maintenance of antihypertensive therapy because
of their similar protection against total and cardiovascular mor-
tality. METHODS: A cost-minimization analysis was performed,
based on numbers-needed-to-treat (NNT) derived from a pub-
lished metaanalysis. An economic model was developed to
compare the 5 alternative interventions: diuretics (chlorthali-
done), â-blockers (propranolol), calcium-channel blockers
(amlodipine), angiotensin-converting enzyme inhibitors (silaza-
pril) and angiotensin receptor blockers (losartan). Cost data were
derived from public sources. Only direct costs were considered
in the analysis including the cost of drug therapy, monitoring,
treating side-effects, poor compliance and switching. All costs
were calculated from a third-party payer perspective, in 2003
Euros. Future costs were discounted at 5%. The time horizon
was 5 years. RESULTS: The total cost to achieve and maintain
hypertension control was 666.21€, 716.69€, 1013.32€, 879.21€,
and 1436.82€ for chlorthalidone, propranolol, amlodipine,
silazapril and losartan respectively. The drug acquisition cost was
20.85%, 29.98%, 53.30%, 45.65%, and 68.22% respectively.
Drug acquisition cost and cost of laboratory monitoring were
more than 85% of the total treatment cost for all the antihy-
pertensive agents. Sensitivity analysis tested the effect of modi-
fying the prices of the antihypertensive agents and laboratory
monitoring, the doses of the alternative drugs and the compli-
ance rate on the economic endpoints and conﬁrmed the superi-
ority of chlorthalidone. CONCLUSIONS: In mild to moderate
hypertension, the 5 major classes of antihypertensive agents
provide similar protection against total and cardiovascular mor-
tality, but diuretics are cheaper than the others. Diuretics should
be considered as the ﬁrst choice of antihypertensive treatment.
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OBJECTIVES: Recent randomised studies have indicated that
Hormone Replacement Therapy (HRT) does not reduce the risk
of cardiovascular events neither in secondary nor in primary pre-
vention. Evidence of the effect of HRT on breast cancer has been
inconclusive, but now the general belief is that the risk of breast
cancer increases. In line with the results found in the Women’s
Health Initiative (WHI) the cost-effectiveness of HRT therapy,
